期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 14, 期 1, 页码 108-111出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2007.10.020
关键词
prognostic biomarkers; DLBCL; gene arrays
资金
- NATIONAL CANCER INSTITUTE [R01CA122105, R01CA109335] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA109335, R01 CA122105, R01 CA122105-02, R01 CA109335-03] Funding Source: Medline
Diffuse large B cell lymphoma (DLBCL) is a subtype of non-Hodgkin lymphoma (NHL), characterized by a markedly heterogeneous clinical course and response to therapy that is not appreciated with standard histopathologic and immunophenotypic evaluations. Recent: studies have focused on the use of genome-scale expression profiles that provide a snap fingerprint of the tumor and identifying tumors with similar genetic alterations and clinical features. Gene expression studies have the ability to recognize distinct subgroups of patients based on similar molecular characteristics and markedly different outcomes that were independent of the International Prognostic Index (IPI). Further, DNA microarray studies also allow identification of new prognostic biomarkers in DLBCL. However, new methods for immunohistochemical analysis of tissue microarray and RNA extraction from paraffin-embedded blocks are required to overcome the major pitfall of this technology-the requirement for fresh tissue. Herein, we summarize the progress made in better prediction of prognosis of DLBCL patients as a result of gene expression profiling. (C) 2008 American Society for Blood and Marrow Transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据